Did you miss out on our ISLH satellite symposium? We now have the symposium available as a webinar to enable you to learn more about multiple myeloma when it’s convenient for you.
We recognize that companies are cutting back on travel-related discretionary spending, so we are bringing our ISLH satellite symposium to you! We now have the symposium available as a webinar to enable you to learn more about multiple myeloma when it’s convenient for you―24 hours a day, 7 days a week.
View our webinar and learn how new diagnostic methods can help advance the care of myeloma patients. Register now!
About Multiple Myeloma
Multiple myeloma is a cancer caused by malignant plasma cells in the bone marrow. It is estimated that there are more than 102,000 cases of myeloma diagnosed worldwide every year, making it the second most prevalent blood cancer1. As new studies and tests shape and transform therapies for the treatment of multiple myeloma, it’s important to stay abreast of emerging trends in patient care.
Attend the symposium and understand:
- The relevance and complexity of coagulopathies associated with myeloma and their relationship to patient therapy
- How improved precision, sensitivity, and specificity help to enhance screening and monitoring of myeloma patients
- The latest regimens for treating and managing patients with myeloma
Dr. Rein Hoedemakers
Clinical Chemist, Jeroen Bosch Hospital, the Netherlands
Prof. Moniek de Maat, Ph.D.
Associate Professor, Coordinator Laboratory Hematology Department of Hematology, Erasmus Medical Center Rotterdam, Amsterdam, the Netherlands
Prof. Stephen Schey
Professor of Plasma Cell Dyscrasia, Kings College Hospital, London, United Kingdom
Learn more about our hematology portfolio, INNOVANCE® VWF Ac2 assay, and Free Light Chains (FLC) kappa and lambda2 assays.
not available for sale in the U.S.